financial statements 135 Hikma PHarmaceuticals Plc annual report 2011 34. net cash from operating activities 2011 2010 note $000 $000 Profit before tax 93,892 120,982 adjustments for: depreciation and amortisation of: property, plant and equipment 35,660 29,091 intangible assets 11,343 9,342 gain on revaluation of previously held equity interest 7,176 loss on disposal of property, plant and equipment 22 376 gain on disposal of intangible assets 91 162 movement on provisions 757 2,488 movement on deferred income 87 159 cost of equity-settled employee share scheme 7,507 4,473 payments of costs directly attributable to acquisitions 5 10,147 7,705 finance income 468 346 interest and bank charges 23,368 13,856 results from associates 1,164 Cash flow before working capital 183,214 180,470 change in trade and other receivables 59,898 10,689 change in other current assets 4,570 322 change in inventories 8,199 19,295 change in trade and other payables 15,987 16,102 change in other current liabilities 1,958 3,091 Cash generated by operations 128,492 185,197 income tax paid 2,095 32,657 Net cash generated from operating activities 126,397 152,540 35. contingent liabilities a contingent liability existed at the balance sheet date in respect of the guarantees and letters of credit totalling usD 82,494,000 2010:usD119,660,000.
the integrated nature of the Groups worldwide operations, involving significant investment in research and strategic manufacturing at alimited number of locations, with consequential cross-border supply routes into numerous end-markets, gives rise to complexity and delay in negotiations with revenue authorities as to the profits on which individual Group companies are liable to tax.
Disagreements with, and between, revenue authorities as to intra-Group transactions, in particular the price at which goods and services should be transferred between Group companies in different tax jurisdictions, has the potential to produce conflicting claims from revenue authorities as to the profits to be taxed in individual territories.
in common with many other companies in the pharmaceutical industry the Group is involved in various legal proceedings considered typical to its business, including litigation relating to employment, product liability and other commercial disputes.
